Drugs / NaPBA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00947544 | Mar 2010 → Aug 2011 | urea cycle disorder | Amgen | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03335488 Comparator | Feb 2018 → Jul 2022 | urea cycle disorder | Amgen | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NaPBA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00947544 ↗ |
| Route | Oral | “NaPBA tablets for oral administration and NaPBA powder for oral, nasogastric, or gastrostomy tube administration” NCT00947544 ↗ |